Anthropic's Nasdaq IPO launch lands Tuesday morning, IFR says

IFR reported Monday that Anthropic plans to kick off its Nasdaq offering Tuesday morning. An offering launch is not the same thing as shares changing hands — the records available don't confirm a Tuesday trading debut. Anthropic's latest registration amendment is dated Nov. 2, and Nasdaq's IPO calendar carries no trading-date confirmation. The company's Oct. 26 announcement laid out a proposed Nasdaq listing under the ticker ANT, with the share count and price range still undetermined. IFR's earlier reporting described a public roadshow followed by pricing the following week, a different stage again.

The launch is the starting gun for the tokenized-stock crowd. Ondo has promised an Anthropic product that is “Launching on IPO day through Ondo Stocks.” Dinari pinned its commitment to trading instead: “When ANT starts trading, it goes live as a dShare™ the same day,” for eligible investors in the U.S. and more than 90 countries.

The two products are not built the same way. Ondo's documentation describes share-backed structured notes — debt instruments rather than direct share ownership, with no shareholder voting rights — and its offerings exclude U.S. persons. Dinari's U.S. guide calls its tokens a secondary ledger for actual securities ownership held through brokerage accounts; those U.S. tokens are non-transferable and barred from DeFi, and issuance requires a completed brokerage order before minting rather than a promised slice at the IPO price.

Existing derivatives have their own triggers, and none of them deliver equity. OKX's terms provide for a proportional adjustment once an official pre-listing disclosure supplies the real share count, designed to hold position value apart from rounding, after which its contracts gradually become standard stock-linked futures. Binance warns that its estimated share count may differ from the actual figure, and that contract size will be adjusted — a change to the units, not to ownership of Anthropic stock. Liquid's ANTH market is cash-settled too, granting no shares or IPO allocation rights, and its market page doesn't spell out how the contract gets handled at an IPO.

Holders of 21Shares' CLAU get continuity rather than stock. The issuer specifies the product will keep synthetic exposure through FalconX-issued notes and perpetual futures after a listing, while a 1% annual product fee and variable funding costs continue to weigh on net asset value.